Wird geladen...
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
Idelalisib is a first-in-class, oral, selective phosphatidylinositol 3-kinase δ inhibitor that offers a chemotherapy-free option for patients with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Clinical trials in iNHL have evaluated idelalisib as monotherapy and as combination th...
Gespeichert in:
| Veröffentlicht in: | Onco Targets Ther |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876096/ https://ncbi.nlm.nih.gov/pubmed/27274288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S102573 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|